13/02/2012
Abbott To Invest €85m In Pharmaceutical Expansion
Abbott plans to invest €85 million at its pharmaceutical manufacturing operation in Sligo. The investment will result in the creation of up to approximately 175 highly skilled jobs. The expansion of the facility will be completed in 2014. The investment is supported by the Irish Government through IDA Ireland.
The expansion will provide additional space for manufacturing operations to support Abbott’s future pharmaceutical pipeline in the key therapeutic areas of virology, oncology and nephrology and provide additional capacity in Abbott's global pharmaceutical manufacturing network. The new jobs that will be created will be highly skilled and include roles in engineering, quality, pharmaceutical science and other science-based areas. The majority of the jobs will be added during the construction phase and the remainder will come on stream post the completion of the expansion. In addition, construction employment will create up to 150 temporary jobs.
"Abbott has had a presence in Ireland for more than 65 years and began manufacturing in the country in 1974. Sligo is an important part of Abbott's pharmaceutical manufacturing network and we are pleased to expand it to support future production needs. The success of our Sligo facility is due to the dedication of its staff and management. This state-of-the-art expansion will enable us to produce innovative therapies that we expect will represent significant advances in the treatment of cancer, chronic kidney disease and viral infections," said Dr. Azita Saleki-Gerhardt, President, Global Pharmaceutical Operations, Abbott.
Barry O'Leary, CEO of IDA Ireland welcomed the announcement and said: "Abbott Ireland is of key importance to Ireland’s life sciences sector and contributes substantially to Ireland's export economy. It is part of a strong cluster of life sciences companies in the Northwest region, which is hugely important to the local economy.’
(CD/GK)
The expansion will provide additional space for manufacturing operations to support Abbott’s future pharmaceutical pipeline in the key therapeutic areas of virology, oncology and nephrology and provide additional capacity in Abbott's global pharmaceutical manufacturing network. The new jobs that will be created will be highly skilled and include roles in engineering, quality, pharmaceutical science and other science-based areas. The majority of the jobs will be added during the construction phase and the remainder will come on stream post the completion of the expansion. In addition, construction employment will create up to 150 temporary jobs.
"Abbott has had a presence in Ireland for more than 65 years and began manufacturing in the country in 1974. Sligo is an important part of Abbott's pharmaceutical manufacturing network and we are pleased to expand it to support future production needs. The success of our Sligo facility is due to the dedication of its staff and management. This state-of-the-art expansion will enable us to produce innovative therapies that we expect will represent significant advances in the treatment of cancer, chronic kidney disease and viral infections," said Dr. Azita Saleki-Gerhardt, President, Global Pharmaceutical Operations, Abbott.
Barry O'Leary, CEO of IDA Ireland welcomed the announcement and said: "Abbott Ireland is of key importance to Ireland’s life sciences sector and contributes substantially to Ireland's export economy. It is part of a strong cluster of life sciences companies in the Northwest region, which is hugely important to the local economy.’
(CD/GK)
Related Northern Ireland Recruitment News Stories
Click here for the latest headlines.
20 July 2009
Harney Opens Dublin Factory
A new state-of-the-art manufacturing plant in Dublin has been officially opened by the Health Minister Mary Harney . It which will house one of Japan's largest pharmaceutical firms and give a boost to employment opportunities.
Harney Opens Dublin Factory
A new state-of-the-art manufacturing plant in Dublin has been officially opened by the Health Minister Mary Harney . It which will house one of Japan's largest pharmaceutical firms and give a boost to employment opportunities.
14 October 2005
Minister opens Recordati Ringaskiddy plant
Minister for Enterprise, Trade and Employment Micheál Martin recently opened the new Active Pharmaceutical Ingredients Plant in Ringaskiddy, Co. Cork, for Recordati S.p.A., a European pharmaceutical group based in Milan, Italy.
Minister opens Recordati Ringaskiddy plant
Minister for Enterprise, Trade and Employment Micheál Martin recently opened the new Active Pharmaceutical Ingredients Plant in Ringaskiddy, Co. Cork, for Recordati S.p.A., a European pharmaceutical group based in Milan, Italy.
28 March 2006
Abbott Investment To Create 155 Jobs
Abbott, one of the world’s largest healthcare companies, is to make a further high value healthcare investment in Ireland of €36 million, with the support of IDA Ireland, to establish a manufacturing facility for its diabetes care products in Donegal Town. It will create 155 high quality jobs with over 45% requiring a third level qualification.
Abbott Investment To Create 155 Jobs
Abbott, one of the world’s largest healthcare companies, is to make a further high value healthcare investment in Ireland of €36 million, with the support of IDA Ireland, to establish a manufacturing facility for its diabetes care products in Donegal Town. It will create 155 high quality jobs with over 45% requiring a third level qualification.
15 November 2002
700 new jobs for Galway and Cavan
US health care giant Abbott Laboratories is to create a total of 700 new jobs in the Irish Republic. In two separate developments over the next five years, Abbott is to develop a research and development centre and expand production facilities at their plant in Galway.
700 new jobs for Galway and Cavan
US health care giant Abbott Laboratories is to create a total of 700 new jobs in the Irish Republic. In two separate developments over the next five years, Abbott is to develop a research and development centre and expand production facilities at their plant in Galway.
30 November 2009
50 Pharma Jobs Expected In Co Waterford
A new pharmaceutical manufacturing company is expected to create 50 new jobs in Lismore, Co Waterford. The company, QM Specials, a subsidiary of UK-based Quantum Specials, has been granted a license by the Irish Medicines Board to produce a range of 'special' medicines.
50 Pharma Jobs Expected In Co Waterford
A new pharmaceutical manufacturing company is expected to create 50 new jobs in Lismore, Co Waterford. The company, QM Specials, a subsidiary of UK-based Quantum Specials, has been granted a license by the Irish Medicines Board to produce a range of 'special' medicines.